Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie

What Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie does

Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie is a Vienna-based non-profit clinical research institute, founded in 2020 and operating under the umbrella of the Karl Landsteiner Gesellschaft (KLG), Austria's largest non-university medical research institution. The institute focuses on lung cancer, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), and runs investigator-initiated studies, Phase II–IV clinical trials, and the LALUCA prospective lung cancer registry, which is described as Austria's largest of its kind and captures diagnostic processes, therapeutic decisions, and disease trajectories in routine clinical practice since its 2020 launch.

The institute's product and service portfolio centers on four lines: (1) the LALUCA registry for real-world data capture and evidence generation; (2) a clinical trials program spanning Phase II through Phase IV studies for oncological therapies, COPD treatments, and ILD therapies; (3) educational offerings including the onTarget webinar series on rare mutations (EGFR, KRAS) and the Kongresshighlights Lung Cancer three-session post-conference series; and (4) participation in the annual Landsteiner Tagung scientific conference. The institute is operationally hosted at Klinik Floridsdorf within the Wiener Gesundheitsverbund and collaborates with an extensive network of Austrian and international academic partners, including Medizinische Universität Wien, Medizinische Universität Graz, Thoraxklinik Heidelberg, University Medical Center Groningen, University of Pittsburgh School of Medicine, and TU Dresden.

As a non-profit association, the institute does not sell products or services to end customers; its revenue derives from research grants, institutional partnerships, and clinical trial sponsorships. Its customer base comprises patients with lung cancer, COPD, and ILD (clinical trial participants and registry subjects), medical professionals (educational program participants), pharmaceutical trial sponsors, and academic research collaborators. Leadership is provided by Prim. Priv.-Doz. Dr. Arschang Valipour (Director) and Christoph Weinlinger, BSc, MSc (Deputy Director), supported by a team of 14 employees at the institute level within a 72-employee KLG organization that spans 67 research institutes and 453 members as of May 2026.

Name

Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie

Legal name

Karl Landsteiner Gesellschaft

Website

https://karl-landsteiner.at

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

The Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie is a Vienna-based non-profit clinical research institute conducting lung cancer, COPD, and ILD research, operating the LALUCA registry and Phase II–IV clinical trials for patients, physicians, and academic partners.

Ownership category

akta.pro rank

Product category

Pulmonary and Thoracic Oncology Clinical Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Thoracic (Lung) Oncology (HLAKAFAL), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Clinical lung cancer research
• Pneumology clinical trials
• Real-world evidence registries
• Thoracic oncology studies
• COPD research

Headquarters

HQ city

Vienna (Floridsdorf)

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Research Funding and Grants: As a non-profit research institute under the Karl Landsteiner Gesellschaft umbrella, funding is derived from research grants, institutional partnerships, and possibly clinical trial sponsorships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

The institute conducts clinical and translational research in lung cancer, COPD, and interstitial lung disease, operating the LALUCA longitudinal lung cancer registry, executing Phase II–IV clinical trials, investigator-initiated studies, and continuing medical education programs including webinar series and annual scientific conferences. Its offerings are aimed at healthcare institutions, pharmaceutical sponsors, and the pneumology/oncology medical community in Austria and Central Europe.

Product overview

Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie operates as a clinically and scientifically oriented research institute under the Karl Landsteiner Gesellschaft umbrella. The institute's portfolio centers on lung cancer, COPD, and interstitial lung disease research. The core offerings include: the LALUCA lung cancer registry (Austria's largest prospective registry since 2020), a clinical trials program spanning Phase II through Phase IV studies, and educational services including the onTarget webinar series and Kongresshighlights Lung Cancer. These offerings work together to advance clinical research, generate real-world evidence, and transfer scientific findings into clinical practice through structured data collection, investigator-initiated studies, and continuing medical education.

Differentiator

Problem solved

Functional benefit

Brands

• LALUCA: Longitudinal Analysis of Lung Cancer Data - Austria's largest prospective lung cancer registry tracking diagnostic processes, therapeutic decisions and disease progression

Products and services

• LALUCA - Longitudinal Analysis of Lung Cancer Data Registry Austria's largest prospective lung cancer registry that captures diagnostic processes, therapeutic decisions, and disease trajectories in clinical routine to generate real-world evidence for differentiated treatment decisions in lung cancer.
• Clinical Trials Program (Phase II, III, IV) Clinical trials program focused on lung cancer, COPD, and interstitial lung disease, encompassing Phase II and III studies as well as Phase IV post-market studies for oncological and respiratory therapies, conducted by the institute at Klinik Floridsdorf.
• onTarget Webinar Series Educational webinar series covering targeted therapy topics in lung cancer, including rare mutations (EGFR, KRAS), molecular variants, and therapeutic approaches, targeted at pneumologists, oncologists, and clinical researchers.
• Kongresshighlights Lung Cancer Webinar Series Annual three-session webinar series presenting key international developments in lung cancer research immediately following major oncology conferences, targeting medical professionals and clinical researchers.
• Landsteiner Tagung (Annual Scientific Conference) Annual scientific conference organized by Karl Landsteiner Gesellschaft focusing on clinical research themes (e.g., "Herz, Hirn und Gefäße" for 2026), bringing together researchers, clinicians, and medical professionals for interdisciplinary knowledge exchange.

Quantifiable outcome

• LALUCA is Austria's largest prospective lung cancer registry
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered major, minor and core.

• Abteilung für Pneumologie, Kepler Universitätsklinikum LinzmajorStrategic or Co-development PartnerScientific cooperation partner in pneumology research.
• Austrian Institute of Technology (AIT)majorStrategic or Co-development PartnerScientific cooperation partner providing technological expertise.
• Christian Doppler Labor für Maschinelles Lernen zur PräzisionsbildgebungmajorStrategic or Co-development PartnerScientific cooperation partner for machine learning and precision imaging research.
• IMP – Research Institute of Molecular PathologymajorStrategic or Co-development PartnerScientific cooperation partner in molecular pathology research.
• Karl Landsteiner Institut für klinische und translationale thoraxchirurgische ForschungmajorStrategic or Co-development PartnerInternal KLG network partner for thoracic surgical research.
• Klinik für Innere Medizin I, Universitätsspital Carl Gustav Carus, TU DresdenmajorStrategic or Co-development PartnerInternational scientific cooperation partner in Germany.
• Klinik Pirawarth in WienminorStrategic or Co-development PartnerClinical cooperation partner in Vienna.
• Ludwig-Boltzmann-Institut für LungengesundheitmajorStrategic or Co-development PartnerPartner in lung health research within the Ludwig Boltzmann association network.
• Medizinische Universität GrazmajorStrategic or Co-development PartnerAustrian academic partner for medical research collaboration.
• Medizinische Universität WienmajorStrategic or Co-development PartnerMajor Austrian academic partner (Medical University of Vienna) for research collaboration.
• Therme Wien MedminorStrategic or Co-development PartnerPartner for therapeutic and rehabilitation research.
• Thoraxklinik, Universitätsklinikum HeidelbergmajorStrategic or Co-development PartnerLeading international partner for thoracic medicine research in Germany.
• Universität WienmajorStrategic or Co-development PartnerAustrian academic partner for university-level research collaboration.
• University Medical Center GroningenmajorStrategic or Co-development PartnerInternational scientific cooperation partner in the Netherlands.
• University of Pittsburgh School of MedicinemajorStrategic or Co-development PartnerMajor international research partner in the United States.
• Wiener GesundheitsverbundcoreStrategic or Co-development PartnerCore institutional partner - host organization for the institute at Klinik Floridsdorf. The Wiener Gesundheitsverbund is the municipal hospital association of Vienna.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medical University of Vienna (Medizinische Universität Wien): Major Austrian medical university with extensive pulmonology and thoracic oncology research programs. Comparable academic research base and a documented major research partner of the institute.
• UPMC Hillman Cancer Center (University of Pittsburgh): Major US academic cancer center running lung cancer clinical trials and translational research. Comparable in translational research scope, and University of Pittsburgh School of Medicine is a documented major research partner of the institute.
• Princess Margaret Cancer Centre (University Health Network): Large North American comprehensive cancer center running lung cancer clinical trials and translational research programs. Comparable in trial scope and translational focus, though at a much larger scale.

Emerging players

• Austrian Institute of Technology (AIT): Austrian non-university applied research organization providing technological and translational expertise. Documented research partner of the institute with overlapping translational research methodology, though broader in scope.
• IMP – Research Institute of Molecular Pathology: Vienna-based molecular pathology research institute conducting basic and translational research relevant to lung cancer biology. Documented partner and comparable research orientation, though more focused on bench research than clinical trials.

Others

• International Association for the Study of Lung Cancer (IASLC): Global professional society for lung cancer research and education, organizing WCLC and publishing the Journal of Thoracic Oncology. Comparable as the broader thoracic oncology community ecosystem, and the journal in which the institute published.

Direct peers

• Ludwig Boltzmann Institut für Lungengesundheit (LBI LSP): Austrian non-university research institute focused on lung health research, including COPD and lung cancer. Directly comparable in mission, funding model, and clinical orientation to the Karl Landsteiner Institut, and also a documented scientific cooperation partner.
• Kepler Universitätsklinikum Linz – Abteilung für Pneumologie: Austrian university hospital department of pneumology conducting clinical research and trials in lung cancer and COPD. Documented as a scientific cooperation partner with overlapping therapeutic area focus.
• European Thoracic Oncology Platform (ETOP): European academic cooperative group running investigator-initiated lung cancer clinical trials and translational research. Comparable in clinical trial conduct and thoracic oncology focus, with broader geographic reach.
• Thoraxklinik am Universitätsklinikum Heidelberg: Leading German specialty hospital for thoracic medicine and lung cancer, conducting clinical trials and translational research in lung cancer and COPD. Directly comparable in clinical trial activity and a documented partner of the institute.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lungenforschung
• Facebookfacebook.com/lungenforschung
• LinkedInlinkedin.com/company/lungenforschung
• Instagraminstagram.com/lungenforschung

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie